BACKGROUND: The aim was to investigate the effect of tiapride (100 mg three times a day for at least one month) on outcome following detoxification. METHOD: The setting was a tertiary referral centre. The study design was randomised, double-blind, and placebo-controlled. One hundred routinely admitted alcohol-dependent patients were entered, and 54 completed the trial. Outcome was assessed by considering drinking status at three months and six months follow-up, and by comparing psychological status at intake and follow-up using the Crown-Crisp Experiential index, the Litman Self-esteem scale and a Satisfaction with Life Situations scale. We also compared performance over the six months before admission with the three and six months of follow-up on measures of health, social and drinking variables. RESULTS:Tiapride proved better (usually at statistically highly significant levels) than placebo at promoting: abstinence, self-esteem, and satisfaction with life situations; and at reducing: alcohol consumption, use of health service resources, and levels of neuroticism. CONCLUSIONS:Tiapride merits serious consideration in the longer-term treatment of alcoholic patients.
RCT Entities:
BACKGROUND: The aim was to investigate the effect of tiapride (100 mg three times a day for at least one month) on outcome following detoxification. METHOD: The setting was a tertiary referral centre. The study design was randomised, double-blind, and placebo-controlled. One hundred routinely admitted alcohol-dependent patients were entered, and 54 completed the trial. Outcome was assessed by considering drinking status at three months and six months follow-up, and by comparing psychological status at intake and follow-up using the Crown-Crisp Experiential index, the Litman Self-esteem scale and a Satisfaction with Life Situations scale. We also compared performance over the six months before admission with the three and six months of follow-up on measures of health, social and drinking variables. RESULTS:Tiapride proved better (usually at statistically highly significant levels) than placebo at promoting: abstinence, self-esteem, and satisfaction with life situations; and at reducing: alcohol consumption, use of health service resources, and levels of neuroticism. CONCLUSIONS:Tiapride merits serious consideration in the longer-term treatment of alcoholicpatients.
Authors: Michael Soyka; Peggy Schmidt; Michael Franz; Thomas Barth; Michael de Groot; Thorsten Kienast; Thomas Reinert; Christoph Richter; Greif Sander Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-08-17 Impact factor: 5.270
Authors: A C Del Re; Natalya Maisel; Janet C Blodgett; Paula Wilbourne; John W Finney Journal: J Clin Psychopharmacol Date: 2013-10 Impact factor: 3.153
Authors: J Altman; B J Everitt; S Glautier; A Markou; D Nutt; R Oretti; G D Phillips; T W Robbins Journal: Psychopharmacology (Berl) Date: 1996-06 Impact factor: 4.530